1. Home
  2. HBT vs CRVS Comparison

HBT vs CRVS Comparison

Compare HBT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HBT Financial Inc.

HBT

HBT Financial Inc.

N/A

Current Price

$35.68

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

N/A

Current Price

$14.56

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HBT
CRVS
Founded
1920
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
HBT
CRVS
Price
$35.68
$14.56
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$30.75
$30.17
AVG Volume (30 Days)
129.7K
757.8K
Earning Date
04-27-2026
05-07-2026
Dividend Yield
3.29%
N/A
EPS Growth
7.96
48.04
EPS
1.12
N/A
Revenue
N/A
N/A
Revenue This Year
$35.73
N/A
Revenue Next Year
$7.01
N/A
P/E Ratio
$32.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.36
$5.29
52 Week High
$37.51
$26.95

Technical Indicators

Market Signals
Indicator
HBT
CRVS
Relative Strength Index (RSI) 58.06 51.49
Support Level $35.34 $14.24
Resistance Level $37.17 $16.66
Average True Range (ATR) 0.73 0.70
MACD -0.25 -0.03
Stochastic Oscillator 41.90 56.16

Price Performance

Historical Comparison
HBT
CRVS

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: